Moreover, as it is known that GSK-3β phosphorylate Axin-bound β-catenin inhibits the translocation of β-catenin in the nucleus, some studies suggest GSK-3β as a target for the osteosarcoma treatment [41,42], while other studies propose the inhibition of GSK-3β as a therapeutic mechanism to repress cell survival and enhance apoptosis in osteosarcoma cells [8]. This evidence concerns the gene GSK3B and osteosarcoma.